Monkeypox virus infections in low-risk groups during the 2022-23 global outbreak: An analysis of the WHO global report
- PMID: 38456029
- PMCID: PMC10917560
- DOI: 10.53854/liim-3201-2
Monkeypox virus infections in low-risk groups during the 2022-23 global outbreak: An analysis of the WHO global report
Abstract
Introduction: In the 2022-23 Mpox outbreak, cases also occurred in children, adolescents, and adults aged 50 years and older, for whom the risk of transmission is low and whose epidemiological characteristics are less known, compared to high-risk groups such as young adults. Here we describe the epidemiological characteristics of Mpox in children, adolescents and adults aged 50 years and older in the global Mpox outbreak.
Methods: A retrospective study on laboratory-confirmed surveillance data of Mpox cases reported to World Health Organization (WHO) was conducted. Case data from WHO's 2022-23 Mpox Outbreak: Global Trends from 1 January 2022 to 1 September 2023 was used for our analysis. We included cases reported by WHO with data on age (children [range, 0 to 9 years], adolescents [range, 10 to 17 years], adults 50 to 59 years, and adults 60 years and older), gender, WHO region, hospital admission, and intensive care unit admission.
Results: Until September 01, 2023, data from 89,752 cases of Mpox have been reported to WHO. Of all the reported cases, 1124 (1.3%), 6296 (7.0%) and 1501 (1.6%) were children and adolescents, adults aged 50-59 years, and adults aged 60 years or older, respectively, and the proportion varied among WHO regions. There was a high proportion of cases among population aged 0-17 years, adolescents (256 [66.3%]) from the region of the Americas and girls aged 0-9 years [127 (46.7%)] from the African region. Men aged 50-59 years (3495 [57.2%] vs. 2553 [41.8%] cases from the region of the Americas and the European region, respectively) and men aged 60-69 years (639 [60.0%] vs. 607 [48.4%] from the region of the Americas and the European region) were most affected, compared to other age groups and women. Among children, adolescents, and adults aged 50 years or older, a low proportion of cases developed some complications and required hospital admission, and some cases were admitted to the intensive care unit.
Conclusions: Epidemiological evidence of Mpox in these low-risk groups highlights the risk of wider community transmission. Therefore, while efforts continue to control the global outbreak of Mpox in high-risk groups, it is also necessary to ensure that these low-risk groups have access to timely health care and vaccination.
Keywords: Monkeypox; adults; children; epidemiology; older adults; outbreak.
Conflict of interest statement
Declaration of competing interest: The authors declare no conflicts of interest.
Figures
Similar articles
-
Mpox in Children and Adolescents during Multicountry Outbreak, 2022-2023.Emerg Infect Dis. 2023 Oct;29(10):2125-2129. doi: 10.3201/eid2910.230516. Epub 2023 Aug 30. Emerg Infect Dis. 2023. PMID: 37647121 Free PMC article.
-
Monkeypox (Mpox) outbreak during COVID-19 pandemic-Past and the future.J Med Virol. 2023 Apr;95(4):e28701. doi: 10.1002/jmv.28701. J Med Virol. 2023. PMID: 36951352 Review.
-
A global update of mpox (monkeypox) in children.Curr Opin Pediatr. 2023 Apr 1;35(2):193-200. doi: 10.1097/MOP.0000000000001232. Epub 2023 Feb 22. Curr Opin Pediatr. 2023. PMID: 36809304 Review.
-
Mpox in people with past infection or a complete vaccination course: a global case series.Lancet Infect Dis. 2024 Jan;24(1):57-64. doi: 10.1016/S1473-3099(23)00492-9. Epub 2023 Sep 4. Lancet Infect Dis. 2024. PMID: 37678309
-
Mpox outbreak in France: epidemiological characteristics and sexual behaviour of cases aged 15 years or older, 2022.Euro Surveill. 2023 Dec;28(50):2200923. doi: 10.2807/1560-7917.ES.2023.28.50.2200923. Euro Surveill. 2023. PMID: 38099346 Free PMC article.
Cited by
-
The Resurgence of Mpox: A New Global Health Crisis.Infez Med. 2024 Sep 1;32(3):267-271. doi: 10.53854/liim-3203-1. eCollection 2024. Infez Med. 2024. PMID: 39282537 Free PMC article. No abstract available.
-
Mpox virus (MPXV): comprehensive analysis of pandemic risks, pathophysiology, treatments, and mRNA vaccine development.Naunyn Schmiedebergs Arch Pharmacol. 2025 Jun;398(6):6143-6163. doi: 10.1007/s00210-024-03649-9. Epub 2025 Jan 8. Naunyn Schmiedebergs Arch Pharmacol. 2025. PMID: 39777535 Review.
-
The Peculiar Emergence of Mpox (Monkeypox): Directions for the Search for the Natural Reservoir and Vaccination Strategies.Vaccines (Basel). 2024 Oct 4;12(10):1142. doi: 10.3390/vaccines12101142. Vaccines (Basel). 2024. PMID: 39460309 Free PMC article.
-
Mpox unveiled: Global epidemiology, treatment advances, and prevention strategies.One Health. 2025 Apr 10;20:101030. doi: 10.1016/j.onehlt.2025.101030. eCollection 2025 Jun. One Health. 2025. PMID: 40630105 Free PMC article. Review.
References
Publication types
LinkOut - more resources
Full Text Sources